News

June 2, 2022

ASCO Annual Meeting 2022

April 18, 2022

AACR Annual Meeting 2022

December 3, 2021

Journal for Immunotherapy of Cancer

September 14, 2021

1st JCA-AACR Precision Cancer Medicine International Conference

July 20, 2021

Journal of Clinical Oncology, An American Society of Clinical Oncology Journal

Immunicom Inc.

HEADQUARTERS

San Diego, CA

RESOURCES

Terms of Use

Privacy Policy

FCOI Policy

GET IN TOUCH

Contact us

Newsletter Subscription

Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe.